ADReCS

Pharmaceutical Information

Drug Name	Clopidogrel
Drug ID	BADD_D00504
Description	Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.[A180547] Clopidogrel was granted FDA approval on 17 November 1997.[L7213]
Indications and Usage	Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213]
Marketing Status	approved
ATC Code	B01AC04
DrugBank ID	DB00758
KEGG ID	D07729; D10823; D10824
MeSH ID	D000077144
PubChem ID	60606
TTD Drug ID	D0N0TZ
NDC Product Code	42543-714; 50090-4918; 52605-083; 16729-218; 0024-1171; 68788-8190; 72578-012; 65977-0037; 52605-082; 63187-362; 63629-4728; 70518-0400; 33342-060; 42543-713; 65162-414; 0093-7314; 16729-219; 61919-007; 67296-1840; 50090-2598; 50090-5781; 0024-1332; 61919-737; 70771-1062; 16714-052; 68071-2813; 68071-4138; 71335-0581
UNII	A74586SNO7
Synonyms	Clopidogrel \| SC 25989C \| SC 25990C \| SR 25989 \| Clopidogrel-Mepha \| Clopidogrel Mepha \| Clopidogrel Sandoz \| Iscover \| Clopidogrel Napadisilate \| Clopidogrel Hydrochloride \| PCR 4099 \| PCR-4099 \| Clopidogrel Besylate \| Clopidogrel Besilate \| Clopidogrel, (+)(S)-isomer \| Plavix \| Clopidogrel Bisulfate

Chemical Information

Molecular Formula	C16H16ClNO2S
CAS Registry Number	113665-84-2
SMILES	COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Tachyarrhythmia	02.03.02.008	0.000064%		Not Available
Anal haemorrhage	24.07.02.029; 07.12.03.004	0.000047%
Quadriparesis	17.01.04.012	0.000203%		Not Available
Left ventricular dysfunction	02.04.02.011	0.000021%
Urethral haemorrhage	24.07.03.006; 20.07.01.003	0.000021%		Not Available
Tongue dry	07.14.02.009	0.000021%		Not Available
Tumour haemorrhage	24.07.01.028; 16.32.03.008	0.000021%
Shock haemorrhagic	24.06.02.014; 14.05.05.003	0.000481%		Not Available
Anal sphincter atony	17.05.02.009; 07.03.01.003	0.000021%		Not Available
Balance disorder	08.01.03.081; 17.02.02.007	-	-	Not Available
Cardiac death	08.04.01.007; 02.03.04.015	0.000053%		Not Available
Bradyphrenia	19.10.03.002; 17.03.03.004	0.000053%		Not Available
Spinal epidural haematoma	24.07.04.020; 17.08.01.038; 12.01.13.006	0.000278%		Not Available
Lupus-like syndrome	23.03.02.004; 10.04.03.003; 15.06.02.004	0.000021%		Not Available
Contusion	15.03.05.007; 24.07.06.001; 23.03.11.002; 12.01.06.001	-	-
Lower gastrointestinal haemorrhage	07.12.03.011; 24.07.02.030	0.000460%
Deep vein thrombosis	24.01.02.003	-	-	Not Available
Lacunar infarction	24.04.06.009; 17.08.01.016	0.000064%		Not Available
Cardiopulmonary failure	22.02.06.004; 02.05.01.004	0.000032%		Not Available
Catheter site haemorrhage	12.07.02.002; 24.07.01.003; 08.02.02.002	0.000043%		Not Available
Puncture site haemorrhage	24.07.01.034; 12.07.04.006; 08.02.04.007	0.000053%		Not Available
Blood pressure inadequately controlled	24.06.01.007	0.000021%		Not Available
Dyschezia	07.02.03.005	0.000021%		Not Available
Facial paresis	17.04.03.002	0.000053%
Bile duct stenosis	09.02.02.001	0.000032%
Systemic inflammatory response syndrome	24.06.03.008; 10.02.01.008; 08.01.05.005	0.000043%		Not Available
Large intestine polyp	16.05.02.006; 07.20.01.010	0.000079%		Not Available
Acute coronary syndrome	24.04.04.011; 02.02.02.015	0.000385%		Not Available
Conjunctival hyperaemia	06.04.01.004	0.000032%		Not Available
Bone erosion	15.02.04.019	0.000021%		Not Available

The 19th Page First Pre 19 20 21 22 23 Next Last Total 27 Pages